Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Pompe Disease Treatment Market
Pompe Disease Treatment Market Size
- Report ID: GMI8315
- Published Date: Feb 2024
- Report Format: PDF
Pompe Disease Treatment Market Size
Pompe Disease Treatment Market size was valued at USD 1.6 billion in 2023 and is expected to grow at a CAGR of 4.4% between 2024 and 2032. Pompe disease, also known as glycogen storage disease type II, is a rare genetic disorder caused by mutations in the GAA gene. It results in deficient activity of the enzyme GAA, leading to the accumulation of glycogen in cells, particularly in muscles, causing progressive weakness and other symptoms.
The market growth is due to the escalated burden of Pompe disease, leading to increased demand for effective treatments. This trend has fueled research activities, including the development of innovative therapeutic approaches like enzyme replacement therapy (ERT) and ongoing studies on alternative therapies. Pompe disease results from acid alpha-glucosidase (GAA) deficiency, with incidence rates varying by ethnicity and region. The highest prevalence occurred in East Asian populations (1 in 12,125). The growing global burden has driven the need for enhanced diagnosis and care access for the patients with rare diseases treatment, thereby bolstering the market growth.
| Report Attribute | Details |
|---|---|
| Base Year: | 2023 |
| Pompe Disease Treatment Market Size in 2023: | USD 1.6 Billion |
| Forecast Period: | 2024 - 2032 |
| Forecast Period 2024 - 2032 CAGR: | 4.4% |
| 2032 Value Projection: | USD 2.3 Billion |
| Historical Data for: | 2018 - 2023 |
| No. of Pages: | 170 |
| Tables, Charts & Figures: | 249 |
| Segments covered: | Treatment Type, Disease Type, Therapy Type, End-user, and Region |
| Growth Drivers: |
|
| Pitfalls & Challenges: |
|
Frequently Asked Questions (FAQ) :
Pompe Disease Treatment Market Scope
